Tenderwize
Wróć do wyszukiwania

Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 250 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or framework maximum is provided. The commercial attractiveness is unknown.

Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive discount agreements for Naltrexone (ATC N07BB04) under §130a Abs. 8 SGB V
  • Contract duration: July 1, 2025 to June 30, 2027
Pokaż pełne podsumowanie

This is an open-house model (non-procurement) for non-exclusive discount agreements on Naltrexone (ATC N07BB04) with AOK Bayern. Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and signed contract documents. The contract runs from July 1, 2025 to June 30, 2027. No estimated value is provided. The notice is published under procurement forms but is explicitly stated not to be a procurement procedure.

Ryzyka

No estimated value or framework maximum is provided. The commercial attractiveness is unknown.

Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Eligibility: only pharmaceutical companies may participate

Administrative

  • Submission of signed contract, annex listing covered medicines, and signed declaration of reliability
  • Documents can be submitted in paper (two originals) or electronically with qualified electronic signature

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria applicable since this is an open-house model with no selection process.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

Non-exclusive discount agreements for the active substance Naltrexone (ATC N07BB04). Eligible pharmaceutical companies can join at any time until May 5, 2027. Contracts are identical and not negotiable. Early termination possible with one-month notice. The open-house agreements automatically cease if a nationwide or regional discount contract is concluded via a formal procurement procedure.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria applicable since this is an open-house model with no selection process.

Termin

Deadline May 05, 2027

Szczegóły zamówienia

Data publikacji
15 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
317360-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30